News >

Frontline Immunotherapy Approval in Small Cell Lung Cancer Sets New Precedent for Progress

Caroline Seymour
Published: Friday, Jul 12, 2019

Anna F. Farago, MD, PhD

Anna F. Farago, MD, PhD
Checkpoint inhibitors have propelled the field of small cell lung cancer (SCLC) forward, and further exploration into novel targets like DLL3, PARP, and activated transcription may move the needle even further, said Anna F. Farago, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x